Patients with immunocompromising conditions were excluded. An additional analysis compared serum antibody levels (anti-spike immunoglobulin G and anti–receptor binding domain IgG) to SARS-CoV-2, the virus that causes COVID-19, among 100 healthy volunteers enrolled at three hospitals 2–6 weeks after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine. hospitals across 18 states during March 11–August 15, 2021. To assess vaccine effectiveness (VE) of these three products in preventing COVID-19 hospitalization, CDC and collaborators conducted a case-control analysis among 3,689 adults aged ≥18 years who were hospitalized at 21 U.S. Current guidelines from FDA and CDC recommend vaccination of eligible persons with one of these three products, without preference for any specific vaccine ( 4, 5). The Pfizer-BioNTech vaccine received FDA approval for persons aged ≥16 years on Aug( 4). A 1-dose viral vector vaccine (Ad26.COV2 from Janssen ) received EUA in February 2021 for persons aged ≥18 years ( 3). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged ≥18 years and aged ≥16 years, respectively. Three COVID-19 vaccines are authorized or approved for use among adults in the United States ( 1, 2). Patel, MD 2,* IVY Network ( View author affiliations) View suggested citation Naioti, MPH 2 Miwako Kobayashi, MD 2 Jennifer R. Hart, MA 1 Yuwei Zhu, MD 1 Lisa Mills, PhD 2 Sandra N. Stubblefield, MD 1 Adrienne Baughman 1 Kelsey N. Exline, MD 22 Natasha Halasa, MD 1 James D. Chang, MD, PhD 19 Christopher Mallow, MD 20 Carolina Rivas 20 Hilary M.
Wilson, MD 18 Alexandra June Gordon, MD 18 Nida Qadir, MD 19 Steven Y. ten Lohuis 16 Abhijit Duggal, MD 17 Jennifer G. Monto, MD 14 Akram Khan, MD 15 Catherine L. Gong, MD 10 Amira Mohamed, MD 10 Daniel J.
Hager, MD, PhD 8 Arber Shehu, MD 8 Matthew E. Mohr, MD 6 Anne Zepeski, PharmD 6 Tresa McNeal, MD 3 ,4 Shekhar Ghamande, MD 3 ,4 Kevin W. Rhoads, PhD 1,* Manjusha Gaglani, MBBS 3 ,4 Adit A.
0 kommentar(er)
